Literature DB >> 3724664

Serology and virulence diversity among Old-World arenaviruses, and the relevance to vaccine development.

P B Jahrling, C J Peters.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3724664     DOI： 10.1007/bf02122441

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN： 0300-8584            Impact factor:   3.402


× No keyword cloud information.
  4 in total

1.  Endemic Lassa fever in Liberia. III. Characterization of Lassa virus isolates.

Authors:  P B Jahrling; J D Frame; S B Smith; M H Monson
Journal:  Trans R Soc Trop Med Hyg       Date:  1985       Impact factor: 2.184

2.  Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin.

Authors:  P B Jahrling
Journal:  J Med Virol       Date:  1983       Impact factor: 2.327

3.  Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain.

Authors:  P B Jahrling; C J Peters
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

4.  Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus.

Authors:  D H Walker; K M Johnson; J V Lange; J J Gardner; M P Kiley; J B McCormick
Journal:  J Infect Dis       Date:  1982-09       Impact factor: 5.226
  4 in total
  9 in total

Review 1.  Coverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model system.

Authors:  Jason Botten; John Sidney; Bianca R Mothé; Bjoern Peters; Alessandro Sette; Maya F Kotturi
Journal:  Microbiol Mol Biol Rev       Date:  2010-06       Impact factor: 11.056

2.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

3.  Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.

Authors:  P Pushko; J Geisbert; M Parker; P Jahrling; J Smith
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein.

Authors:  J ter Meulen; M Badusche; K Kuhnt; A Doetze; J Satoguina; T Marti; C Loeliger; K Koulemou; L Koivogui; H Schmitz; B Fleischer; A Hoerauf
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

5.  T cell-dependence of Lassa fever pathogenesis.

Authors:  Lukas Flatz; Toni Rieger; Doron Merkler; Andreas Bergthaler; Tommy Regen; Mariann Schedensack; Lukas Bestmann; Admar Verschoor; Mario Kreutzfeldt; Wolfgang Brück; Uwe-Karsten Hanisch; Stephan Günther; Daniel D Pinschewer
Journal:  PLoS Pathog       Date:  2010-03-26       Impact factor: 6.823

6.  Evaluation of Lassa antiviral compound ST-193 in a guinea pig model.

Authors:  Kathleen A Cashman; Mark A Smith; Nancy A Twenhafel; Ryan A Larson; Kevin F Jones; Robert D Allen; Dongcheng Dai; Jarasvech Chinsangaram; Tove' C Bolken; Dennis E Hruby; Sean M Amberg; Lisa E Hensley; Mary C Guttieri
Journal:  Antiviral Res       Date:  2011-03-01       Impact factor: 5.970

Review 7.  Improving the Breadth of the Host's Immune Response to Lassa Virus.

Authors:  Juan Carlos Zapata; Sandra Medina-Moreno; Camila Guzmán-Cardozo; Maria S Salvato
Journal:  Pathogens       Date:  2018-10-28

8.  ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge.

Authors:  Robert J Fischer; Jyothi N Purushotham; Neeltje van Doremalen; Sarah Sebastian; Kimberly Meade-White; Kathleen Cordova; Michael Letko; M Jeremiah Matson; Friederike Feldmann; Elaine Haddock; Rachel LaCasse; Greg Saturday; Teresa Lambe; Sarah C Gilbert; Vincent J Munster
Journal:  NPJ Vaccines       Date:  2021-03-02       Impact factor: 7.344

9.  A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease.

Authors:  Maya F Kotturi; Jason Botten; John Sidney; Huynh-Hoa Bui; Lori Giancola; Matt Maybeno; Josie Babin; Carla Oseroff; Valerie Pasquetto; Jason A Greenbaum; Bjoern Peters; Joey Ting; Danh Do; Lo Vang; Jeff Alexander; Howard Grey; Michael J Buchmeier; Alessandro Sette
Journal:  PLoS Pathog       Date:  2009-12-18       Impact factor: 6.823
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.